Daré Bioscience wins new US patent covering topical lopinavir-ritonavir formulation for DARE-HPV program

• Daré Bioscience secured U.S. Patent No. 12,678,439 covering topical lopinavir-ritonavir formulations for HPV-related cervical disorders.
• Protection is expected to extend into at least 2039, strengthening IP around its investigational DARE-HPV vaginal insert program.
• DARE-HPV is in a Phase 2 trial in about 100 women; topline results are expected in 2027.
• Program funding includes about USD 10 million from ARPA-H, alongside a USD 2 million NIAID award.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280820PRIMZONEFULLFEED9834614) on September 28, 2026, and is solely responsible for the information contained therein.